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serotonin-3–receptor antagonists might have a sex-speciﬁc ef-
fect in patients with irritable bowel syndrome with diarrhea
(IBS-D). Alosetron has been approved for the treatment of only
women, and ramosetron has been approved for the treatment
for only men. We performed a randomized, placebo-controlled,
phase 3 study to determine whether ramosetron reduces
symptoms of IBS-D in women. METHODS: We performed a
prospective study of 576 female outpatients with IBS-D
(according to the Rome III criteria), from February 2013
through February 2014, at 70 academic Gastroenterology De-
partments in Japan. After a 1-week baseline period, subjects
received either 2.5 mg ramosetron (n ¼ 292) or placebo (n ¼
284) once daily for 12 weeks. Primary end points were the
monthly rates of response for relief from overall IBS symptoms
and increased stool consistency at the last evaluation point.
Quality of life (QOL) also was quantiﬁed. RESULTS: A signiﬁ-
cantly higher proportion of patients given ramosetron re-
ported global improvement (50.7%; 95% conﬁdence interval
[CI], 44.8–56.6) than patients given placebo (32.0%; 95%
CI, 26.7–37.8)—a difference of 18.6% (95% CI, 10.7–26.5; P <
.001). The relative risk was 1.58 (95% CI, 1.29–1.94) and the
number needed to treat was 6 (95% CI, 4–10). A signiﬁcantly
higher proportion of patients in the ramosetron group reported
increased stool consistency (40.8%; 95% CI, 35.1%–46.6%)
than in the placebo group (24.3%; 95% CI, 19.4%–29.7%)—a
difference of 16.5% (95% CI, 8.9%–24.0%; P < .001). Patients
receiving ramosetron had signiﬁcant reductions in abdominal
pain and discomfort (P ¼ .001) and greater improvement in
QOL (P ¼ .002) compared with placebo. Ramosetron induced
constipation in 11.0% of patients. CONCLUSIONS: In a ran-
domized, placebo-controlled study of 576 women with IBS-D,
2.5 mg ramosetron per day reduced symptoms and increased
stool consistency and QOL. Clinicaltrials.gov no: NCT01870895.Abbreviations used in this paper: BSFS, Bristol Stool Form Scale; CI,
conﬁdence interval; FDA, Food and Drug Administration; 5-HT,
5-hydroxytryptamine; 5-HT3, 5-hydroxytryptamine receptor 3; IBS, irritable
bowel syndrome; IBS-D, irritable bowel syndrome with diarrhea; MCID,
minimal clinically important difference; NNH, number needed to harm;Keywords: 5-Hydroxytryptamine-3–Receptor Antagonist;
Abdominal Pain; Discomfort; 5-HT.
rritable bowel syndrome (IBS) is a common disorder
1NNT, number needed to treat; QOL, quality of life; RR, relative risk.
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Open access under CC BY-NC-ND license.Iof the gastrointestinal system. The effect of IBS on
society is now well recognized because IBS causes a pro-
found disturbance in the quality of life (QOL) of individuals,
causes economic loss to individuals and society,2 and in-
creases the risk of developing depressive and anxietydisorders, similar to other functional gastrointestinal dis-
orders.3 IBS, as deﬁned by the Rome III criteria,4 is classiﬁed
into 4 subtypes: IBS with diarrhea (IBS-D), IBS with con-
stipation, mixed-type IBS, and unsubtyped IBS. Among these
subtypes, patients with IBS-D, together with IBS with con-
stipation, have more well-deﬁned phenotypes to use as a
basis for the development of pharmacotherapy.5
Many agents have been developed for IBS-D, and evi-
dence for the 5-hydroxytryptamine receptor 3 (5-HT3)
antagonist, alosetron, has shown that it suppresses the
cardinal symptoms of IBS-D.6,7 However, serious adverse
drug reactions including ischemic colitis mandate that the
use of alosetron be limited to a specialist prescription.7,8
Moreover, alosetron has been approved in the United
States only for female patients.6 Another 5-HT3 antagonist,
ramosetron,9–11 was developed in Japan, initially for nausea
in cancer patients receiving chemotherapy, and later for IBS-
D.12–14 No ischemic colitis was reported in 901 IBS-D pa-
tients who received ramosetron in a previous study.12–15 In
contrast to alosetron, the clinical efﬁcacy of ramosetron for
IBS-D has been shown only in men.12–15 These data resulted
in the use of ramosetron being limited to male patients with
IBS-D in Japan,12–14 Korea,15 and Thailand. There is, how-
ever, no logical explanation why 5-HT3 antagonists would
be effective solely in women with IBS-D in Western coun-
tries and only in men with IBS-D in Asian countries. Values
for relative risk (RR) with alosetron and cilansetron have
been reported to be lower in studies that included only
women (1.23; 95% conﬁdence interval [Cl], 1.14–1.32)
compared with studies including both sexes or men alone
(1.39; 95% CI, 1.28–1.51; RR ratio, 0.88; 95% CI,
0.76–0.98).7
Given the preceding context, it is natural to test the
hypothesis that ramosetron also could be effective in female
February 2016 Ramosetron in IBS-D 359patients with IBS-D in a study with a sufﬁcient sample size.
This study aimed to verify this hypothesis, and provide
compelling evidence and a rationale for the use of 5-HT3
antagonists in patients with IBS-D, regardless of sex.CL
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Patient Population
This study was conducted from February 2013 to February
2014 at 70 Japanese centers that have Gastroenterology De-
partments. Female outpatients aged 20–64 years were diag-
nosed as having IBS-D according to the Rome III criteria.4 The
study protocol was designed in accordance with the Declara-
tion of Helsinki and was approved by the institutional review
boards at all sites. All patients provided written informed
consent before participating in study-related procedures. Pa-
tients satisfying the inclusion and exclusion criteria were
monitored during a 1-week baseline period during which data
on the severity of abdominal pain/discomfort and stool con-
sistency16 were collected to ensure that patients met the
criteria. See the Patient Population section in the Supplemen-
tary materials for more detail.
Study Design
Based on previous studies,12–14 this randomized, double-
blind, placebo-controlled clinical study comprised a provi-
sional registration period, a 1-week baseline period, and a
12-week treatment period. After the baseline period, eligible
patients were assigned randomly to 12 weeks of oral treatment
with placebo or ramosetron hydrochloride (2.5 mg once daily)
before breakfast. Visits were scheduled at weeks 2, 4, 8, and 12
(or at the time of discontinuation) to assess treatment efﬁcacy,
drug compliance, and occurrence of adverse events. Randomi-
zation was performed in a 1:1 ratio using a block size of 4
with a web-based randomization system. The randomization
schedule was developed by a third-party contract research
organization (EPS Corporation, Tokyo, Japan). All patients,
investigators, and sponsors were blinded until all observations
and evaluations were completed, statistical analysis plans were
ﬁnalized, and all data had been locked. All authors had access
to the study data and reviewed and approved the ﬁnal
manuscript.
Data Collection
During the baseline and treatment periods, patients recor-
ded their IBS symptoms each day on paper diary cards at
bedtime, and electronically entered data into a database daily
using an interactive voice response system to support the
completion of data entry in the paper diary cards. This system
of evaluating IBS symptoms has been reported previously as
reliable and valid.12–14 Patients were assessed for disease-
speciﬁc health-related QOL17 every 4 weeks using the Japa-
nese version of the IBS-QOL measurement instrument.18 See
the Supplementary Data Collection section for more detail.
Efﬁcacy and Safety End Points
One of the co-primary end points was monthly responder
rates for global assessment of relief from overall IBS symptoms
at the last evaluation point. The Pharmaceuticals and MedicalDevices Agency of Japan approved use of this measure as a
primary end point for IBS studies in 2002.12,13 Patients with
scores of 0 or 1 at each weekly evaluation point were regarded
as weekly responders, and patients who were weekly re-
sponders for at least 2 of the 4 weeks were regarded as
monthly responders.
Another co-primary end point was the monthly responder
rate for improvement in stool consistency at the last evaluation
point. The US Food and Drug Administration (FDA) proposed a
study design for clinical trials focused on IBS,5 suggesting use
of abdominal pain and stool consistency as co-primary end
points for IBS-D. Importantly, the FDA guidance permits trials
of drugs that target only one of these end points if the mech-
anism of action of the drug applies to only one of these
symptoms.5
Secondary end points included relief of abdominal pain/
discomfort and improvement in abnormal bowel habits. Scales
measuring IBS symptoms, including severity of abdominal
pain/discomfort, the Bristol Stool Form Scale (BSFS), stool
frequency, urgency and feeling of incomplete evacuation, and
IBS-QOL also were established for the secondary end points. All
adverse events were recorded during the intervention period.
See the Supplementary Efﬁcacy and Safety End Points section
for more detail.
Statistical Analysis
Sample sizes of 580 patients (290 patients/group) were
calculated to provide 90% power to detect both a difference in
monthly responder rates for global assessment of relief from
overall IBS symptoms at the last evaluation point between the
placebo group (38%) and the 2.5-mg ramosetron group (53%),
and monthly responder rates for improvement in stool con-
sistency at the last evaluation point between the placebo group
(21%) and the 2.5-mg ramosetron group (40%) based on the
subpopulation of the phase II clinical study (Clinicaltrials.gov
ID: NCT01274000),19 using a c2 test with a 2-sided signiﬁ-
cance level of 0.05. Efﬁcacy analyses included the full analysis
set, which was as complete as possible and as close as possible
to the intention-to-treat ideal of including all randomized
subjects.20 This analysis was in keeping with the International
Conference on Harmonisation E9, generated by the regulatory
authorities and pharmaceutical industries of the European
Union, United States, and Japan, based on each party’s agree-
ment.20 The full analysis set included all patients who received
at least one dose of the study drug during the treatment period
and for whom more than one end point could be evaluated.
Safety analyses were performed for all patients who received at
least one dose of the study drug during the treatment period.
Monthly responder rates for global assessment of relief
from overall IBS symptoms at the last evaluation point are
expressed as a percentage of responders, and 95% CIs are
provided. The treatment groups were compared using a c2 test
with a 2-sided signiﬁcance level of 0.05. Other monthly
responder rate parameters were analyzed similarly. Missing
values were treated as nonresponders. The superiority of
2.5 mg ramosetron over placebo was established by showing a
statistically signiﬁcant difference compared with placebo for
both co-primary end points. BSFS and changes in stool fre-
quency were evaluated using the t test. To compare the
ramosetron group with the placebo group, analysis of covari-
ance was performed with the treatment groups as a factor and
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IBS-QOL and IBS-QOL subscale scores at each evaluation point
from baseline. In addition, the RR and number needed to treat
(NNT) for monthly responder rates for global assessment of
relief from overall IBS symptoms at the last evaluation point
and the monthly responder rate for improvement in stool
consistency at the last evaluation point were calculated.
Adverse events were evaluated using the Fisher exact test, and
the RR and number needed to harm (NNH) for constipation and
hard stool were calculated as post hoc analyses. Ad hoc ana-
lyses also were performed based on the deﬁnition of a
responder speciﬁed in the FDA guidance.5 Responder rates
with respect to abdominal pain/discomfort intensity, stool
consistency, and a composite of abdominal pain/discomfort
intensity and stool consistency were calculated in patients with
the same denominator as the primary end points and in pa-
tients who satisﬁed the eligibility criteria speciﬁed in the FDA
guidance.5 See the Supplementary Statistical Analysis section
for more detail.Results
Overall Study Population
The overall study population is shown in Supplementary
Figure 1. Demographics and baseline characteristics did not
differ between the groups (Table 1). The medication
compliance rate was 98.5% in the placebo group and 95.9%
in the ramosetron group. See the Overall Study Population
section for more detail.
Evaluation of the Primary End Point
Ramosetron-treated patients showed signiﬁcantly higher
responder rates for global assessment of relief from overall
IBS symptoms at the last evaluation point (50.7%; 95% CI,
44.8–56.6) than placebo-treated patients (32.0%; 95% CI,
26.7–37.8; difference, 18.6%; 95% CI, 10.7–26.5; P < 0.001)
(Figure 1A). The RR and NNT were 1.58 (95% CI, 1.29–1.94)
and 6 (95% CI, 4–10), respectively (post hoc analyses)
(Table 2). The monthly responder rate for improvement in
stool consistency was 40.8% (95% CI, 35.1–46.6) in the
ramosetron group and 24.3% (95% CI, 19.4–29.7) in the
placebo group (difference, 16.5%; 95% CI, 8.9–24.0; P <
.001) (Figure 1B). The RR and NNT were 1.68 (95% CI,
1.31–2.15) and 7 (95% CI, 5–12), respectively (post hoc
analyses). Therefore, for both primary end points in the
ramosetron group, responses were signiﬁcantly superior to
those of the placebo group. At every other evaluation pointTable 1.Demographics and Baseline Characteristics of the Tre
Patient background Placebo (n ¼
Age (y) 41.5 ± 12.0
Duration of disease (mo) 158.8 ± 138.
Severity of abdominal pain/discomfort (0–4) 1.79 ± 0.64
Bristol Stool Form Scale (1–7) 5.30 ± 0.55
Stool frequency (times/d) 2.17 ± 1.03for both primary end points, the monthly responder rates of
the ramosetron group also were signiﬁcantly higher than
that of the placebo group. Furthermore, weekly responder
rates were examined to evaluate response onset and sus-
tainability (Supplementary Figure 2A and B). A statistically
signiﬁcant improvement was observed for every week
except week 1 for global assessment of relief from overall
IBS symptoms.Evaluation of Secondary End Points
In the ramosetron group, the monthly responder rate for
abdominal pain/discomfort was signiﬁcantly higher than
that in the placebo group (Figure 2A), except for month 2.
Changes in the severity of abdominal pain/discomfort from
baseline per week were as follows: -0.67 ± 0.84 (means ±
SD) in the ramosetron group and -0.52 ± 0.83 in the placebo
group in the last week of treatment. At weeks 1, 2, 3, and 9,
and the last week of treatment, a signiﬁcant reduction was
observed in the ramosetron group compared with the pla-
cebo group. All monthly responder rates for improvement in
abnormal bowel habits also were signiﬁcantly higher in the
ramosetron group than in the placebo group (Figure 2B).
Weekly BSFS scores and change in weekly stool frequencies
showed signiﬁcantly greater improvement in the ramose-
tron group than in the placebo group throughout the
treatment period (data not shown). Furthermore, daily BSFS
scores were signiﬁcantly lower in the ramosetron group
(4.7 ± 1.3 at day 2) than those in the placebo group (5.0 ±
1.3 at day 2; P ¼ .018) throughout the ﬁrst 14 days after day
2 (Figure 2C).
The change in daily stool frequency at day 2 was
signiﬁcantly greater in the ramosetron group (-0.57 ± 1.17
at day 2) than in the placebo group (-0.25 ± 1.11 at day 2; P
< .001). A signiﬁcant improvement was observed on almost
all days throughout the ﬁrst 14 days, after day 2
(Figure 2D).
On analysis of IBS-QOL, greater improvements were
observed in the ramosetron group than in the placebo group
(Figure 2E). Signiﬁcantly greater improvements in change of
overall scores were observed at the last evaluation point in
the ramosetron group (adjusted mean, 18.3; 95% CI,
16.7–19.9) than in the placebo group (14.6; 95% CI,
12.9–16.2; P ¼ .002). A signiﬁcantly greater improvement in
change of dysphoria (25.6; 95% CI, 23.5–27.7), interference
with activity (22.8; 95% CI, 20.7–24.8), and food avoidance
(21.8; 95% CI, 19.4–24.1) was seen in the ramosetron groupatment Groups
284) Ramosetron 2.5mg (n ¼ 292) P value
41.4 ± 11.8 .871
4 158.4 ± 138.1 .974
1.73 ± 0.68 .352
5.34 ± 0.56 .346
2.22 ± 1.03 .555
Figure 1. Primary end points that indicate the efﬁcacy of
ramosetron. (A) Monthly responder rates for relief from overall
IBS symptoms. (B) Monthly responder rates for improvement
in stool consistency. Height: responder rate (%). Error bar:
95% CI. P values were calculated using a c2 test, as follows:
**P ¼ .001 and ***P < .001.
Table 2.Efﬁcacy and Adverse Event Parameters
Parameters Value 95% CI
Global improvement
Difference 18.6% 10.7–26.5
Relative risk 1.58 1.29–1.94
Number needed to treat 6 4–10
Stool consistency
Difference 16.5% 8.9–24.0
Relative risk 1.68 1.31–2.15
Number needed to treat 7 5–12
Constipation
Relative risk 2.39 1.28–4.47
Number needed to harm 15 9–48
Hard stool
Relative risk 4.01 2.38–6.76
Number needed to harm 5 4–8
GI adverse event
Relative risk 1.95 1.42–2.66
Number needed to harm 6 4–11
Any adverse event
Relative risk 1.27 1.06–1.51
Number needed to harm 8 5–32
CI, conﬁdence interval; GI, gastrointestinal.
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P ¼ .002; 16.7; 95% CI, 14.7–18.8; P < .001; 16.9; 95% CI,
14.5–19.3; P ¼ .004, respectively).
Based on the eligibility criteria and the deﬁnition of a
responder as speciﬁed in the FDA guidance,5 ad hoc ana-
lyses were performed. The responder rate for abdominal
pain/discomfort intensity in the ramosetron group (92 of
173; 53.2%) was signiﬁcantly higher than that in the pla-
cebo group (68 of 175; 38.9%; P ¼ .010) (Figure 3A). The
responder rate for stool consistency in the ramosetron
group (111 of 173; 64.2%) was signiﬁcantly higher than
that in the placebo group (79 of 175; 45.1%; P < .001)
(Figure 3B). The composite (abdominal pain/discomfort and
stool consistency) responder rate in the ramosetron group
(72 of 173; 41.6%) was signiﬁcantly higher than that in the
placebo group (44 of 175; 25.1%; P ¼ .002) (Figure 3C).
Even in subjects who only met the FDA’s deﬁnition of a
responder5 but did not meet the eligibility criteria, the
composite responder rate in the ramosetron group still was
signiﬁcantly higher than that in the placebo group. See the
Supplementary Results section for more detail.Safety
Safety was evaluated in 576 patients. Adverse events
were observed in 154 patients (52.7%) in the ramosetron
group and in 118 patients (41.5%; P ¼ .008) in the placebo
group (Table 3). Serious adverse events including anemia (1
patient) and infectious enterocolitis (1 patient) occurred
only in the placebo group. The incidences of constipation
and hard stool considered to be caused by the pharmaco-
logic action of ramosetron were signiﬁcantly higher in the
ramosetron group (11.0% and 22.6%, respectively) than in
the placebo group (4.6%, P ¼ .005; and 5.6%, P < .001,
respectively). The RR of constipation for ramosetron and the
NNH were 2.39 (95% CI, 1.28–4.47) and 15 (95% CI, 9–48),
respectively (post hoc analyses) (Table 2). The RR of hard
stool for ramosetron and NNH were 4.01 (95% CI,
2.38–6.76) and 5 (95% CI, 4–8), respectively (post hoc an-
alyses). However, these adverse events all were mild except
for one patient who showed a moderate level of hard stool
that, however, recovered immediately.Discussion
This study provides compelling evidence for the use of
ramosetron in female patients with IBS-D. There was no
logical biological explanation why a drug from the same
class, 5-HT3 antagonists, would be effective only in women
with IBS-D in the United States6 and in men with IBS-D in
Japan.12,13 We carefully designed this clinical study with
particular consideration of the optimal dose (2.5 mg) of
ramosetron and the primary end points based on our recent
phase IV study in men with IBS-D14 and phase II study in
women with IBS-D (Clinicaltrials.gov ID: NCT01274000,
unpublished study). The present study has solved the long-
standing anomaly of why 5-HT3 antagonists appeared to be
effective in women with IBS-D only in the United States and
in men with IBS-D only in Asia. This study has shown that
Figure 2. Secondary end points supporting the efﬁcacy of ramosetron. (A) Monthly responder rates for relief of abdominal
pain/discomfort. Column height: responder rate (%). Error bar: 95% CI. P values were calculated using a c2 test, as follows:
*P ¼ .032, **P ¼ .001, ***P < .001. (B) Monthly responder rates for improvement in abdominal bowel habits. Column height:
responder rate (%). Error bar: 95% CI. P values were calculated using a c2 test, as follows: ***P < .001. (C) Daily changes in
BSFS scores. Line graph: mean ± 95% CI. P values were calculated using the t test, as follows: *P ¼ .018 and ***P < .001. (D)
Daily changes in stool frequency. Line graph: means ± 95% CI. P values were calculated using the t test, as follows: *P < .05,
**P < .01, and ***P < .001. (E) Changes in overall scores on the Japanese version of irritable bowel syndrome-quality of life
(IBS-QOL-J) from baseline to the last evaluation point. Column height: the values adjusted by using the baseline score as a
covariate. Error bar: 95% CI. P values were calculated using analysis of covariance with the treatment group as a factor and
baseline score as a covariate, as follows: **P < .01 and ***P < .001 compared with placebo.
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Figure 3. Responder eval-
uation based on FDA
guidance. Column height:
responder rate (%). Error
bar: 95%CI. P values were
calculated using a c2 test,
as follows: *P¼ .010, **P¼
.002, and ***P < .001.
Analysis was ad hoc and
based on eligibility criteria
and the deﬁnition of a
responder speciﬁed in
the FDA guidance.5 (A)
Responder rates for in-
tensity of abdominal pain/
discomfort at the last
evaluation point. (B)
Responder rates for stool
consistency at the last
evaluation point. (C) Com-
posite responder rates for
abdominal pain/discom-
fort and stool consistency
at the last evaluation point.
Table 3. Incidence of Adverse Events
Event
Placebo
(n ¼ 284)
Ramosetron
2.5mg (n ¼ 292)
P
value
All adverse events 118 (41.5%) 154 (52.7%) .009
Gastrointestinal disorders 46 (16.2%) 92 (31.5%) <.001
Constipation 13 (4.6%) 32 (11.0%) .005
Hard stool 16 (5.6%) 66 (22.6%) <.001
Infections and infestations 54 (19.0%) 56 (19.2%) 1.000
Nasopharyngitis 34 (12.0%) 34 (11.6%) 1.000
Pharyngitis 5 (1.8%) 6 (2.1%) 1.000
NOTE. Data are expressed as numbers (%). Events with an
incidence of  2% in the ramosetron group are listed.
P values were calculated using Fisher’s exact test (post hoc
analyses).
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patients with IBS-D, regardless of nationality.
Ramosetron is a tetrahydrobenzimidazole derivative and
a potent and selective 5-HT3 antagonist used for male pa-
tients with IBS-D in Japan,12–14 Korea,14 and Thailand. The
mechanism is believed to be inhibition of the 5-HT3 receptor
in the myenteric plexus and vagal afferent neurons.21 The
peristaltic reﬂex is mediated physiologically by 5-HT3 re-
ceptors in the myenteric plexus.22 Patients with IBS-D show
exaggerated colonic motility in response to colonic disten-
sion23 and secretion of 5-HT.24 Abnormal neurotransmis-
sion of 5-HT via the 5-HT3 receptors has been reported in
IBS-D patients.25 In rats, ramosetron clearly reduces stress-
induced diarrhea and defecation caused by corticotropin-
releasing hormone.10,11 Ramosetron also increases the
threshold of abdominal pain induced by colonic distension
in rats.26 The results of the present study are considered to
reﬂect these mechanisms of ramosetron.
This study indicates that 2.5 mg/day of ramosetron is an
effective treatment for female patients with IBS-D. Incontrast, the optimal dose of ramosetron for male patients
with IBS-D is 5 mg/day.12–15 Several factors responsible for
such differences have been suggested.27,28 These include
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transit in females with IBS-D as compared with males,29
more systemic exposure to alosetron associated with inhi-
bition of cytochrome P450 CYP1A2 in women than in men,30
and central effects of alosetron that depend on sex,31 with
inhibition of brain regions that predominantly are activated
in females in response to colorectal distension.32 Whatever
the ultimate mechanisms are, women with IBS-D need half
the dose of ramosetron compared with men with IBS-D.
In this study, ramosetron improved stool consistency but
also occasionally triggered constipation. Although no direct
comparison was made, ramosetron in this study had a lower
RR for constipation (2.39; 95% CI, 1.28–4.47) than was the
case for alosetron and cilansetron (RR, 4.28; 95% CI,
3.28–5.60).7 Moreover, 9 cases of ischemic colitis were re-
ported in 4337 IBS patients administered either alosetron
or cilansetron in clinical studies (0.2%).7 In contrast, no case
of ischemic colitis was reported in the 2040 IBS patients in
the pooled clinical study data for ramosetron (0%). On ex-
amination of surveillance data acquired after the clinical use
of ramosetron in Japan, ischemic colitis was observed in 4
cases among an estimated 367,539 IBS-D patients (0.001%)
(unpublished data). This incidence is much lower than the
incidence of deﬁnitively diagnosed ischemic colitis based on
reports of natural observations from the United States (12.6
per 100,000; 95% CI, 11.3–14.0).33 Therefore, these data
suggest the high efﬁcacy of ramosetron with few serious
adverse drug reactions.
IBS-QOL is a reliable and well-validated outcome for
assessing QOL in IBS patients.17,18 The minimal clinically
important difference (MCID) of the total score of the IBS-QOL
is between 10 and 14.34 In this study, the change in total IBS-
QOL scores of the ramosetron group improved and the lower
limit of the 95%CI exceeded theMCID benchmark (18.3; 95%
CI, 16.7–19.9). In contrast, the lower limit of the 95%CI of the
placebo group did not exceed the MCID benchmark (14.6;
95% CI, 12.9–16.2). Because dysphoria, interference with
activity, and food avoidance improved to a greater extent
with ramosetron than with placebo, appropriate adminis-
tration of ramosetron to female patientswith IBS-D is likely to
induce a clinically meaningful improvement.
This study had a number of strengths. First, the positive
effect of ramosetron on women with IBS-D has been shown
not only by the co-primary end points analyses but also by
the ad hoc analyses, which were performed in accordance
with FDA guidance.5 In particular, composite (abdominal
pain/discomfort and stool consistency) responder rates in
the ramosetron group were higher than the rates for the
placebo group regardless of whether or not subjects met the
FDA’s deﬁnition of a responder.5 Therefore, ramosetron has
shown sufﬁcient efﬁcacy to satisfy the criteria in the FDA
guidance for IBS treatment. Second, the patient population
was severely affected based on the mean intensity scores for
abdominal pain/discomfort. From the data obtained in
earlier clinical trials (NCT00918411, unpublished), these
scores correspond to severe symptoms on the average from
the irritable bowel severity scoring system.35 This suggests
that ramosetron also has an effect on severe patients, and
not only mild and moderate patients.This study had some limitations. First, we designed this
study with abdominal pain/discomfort as one of the sec-
ondary end points. The FDA recommends that drugs for IBS
should be developed speciﬁcally to treat the co-primary
end points of abdominal pain and abnormal defecation.5
However, this guidance permits investigators to design
studies with only one of these end points if the mechanism
of action of the drug applies to only one of these symp-
toms.5 Although this study showed that ramosetron is an
effective treatment for abdominal pain/discomfort, in
previous studies global improvement rather than the relief
of abdominal pain/discomfort was considered an appro-
priate indicator of the action of ramosetron in antagonizing
5-HT3 receptors in female Japanese patients with IBS-D
when seeking to obtain Pharmaceuticals and Medical De-
vices Agency approval,36 and also in terms of major cul-
tural considerations.36 Second, the method used to rate
abdominal pain/discomfort was based on previous
studies12–14 and not on the FDA recommendation.5 The
methods used (5-point scale, 0–4) were compatible with
those in the FDA recommendation but use of an identical
11-point (0–10) scale and independent evaluation of
abdominal pain and discomfort may be considered in a
future study. Third, abdominal bloating was not measured
in this study. It should have been assessed reliably with
questionnaires in the same way as pain and other subjec-
tive symptoms. See the Supplementary Discussion section
for more detail.
In conclusion, the study results suggest that 2.5 mg of
ramosetron is useful for treating female patients with IBS-D.
This 5-HT3 antagonist is likely to be beneﬁcial not only for
men but also for women. Based on this study and previous
studies, ramosetron has been shown to be the most prom-
ising 5-HT3 antagonist for treating patients with IBS-D
regardless of sex.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Patients and Methods
Supplementary Patient Population
IBS was deﬁned as recurrent abdominal pain/discom-
fort on at least 3 days per month in the preceding 3 months,
associated with 2 or more of the following: improvement
with defecation, onset associated with a change in the fre-
quency of stools, and/or onset associated with a change in
the form (appearance) of stools.1 Stool consistency was
classiﬁed using the BSFS2 as follows: type 1, separate hard
lumps like nuts (difﬁcult to pass); type 2, sausage shaped
but lumpy; type 3, like a sausage but with cracks on its
surface; type 4, like a sausage or snake, smooth and soft;
type 5, soft blobs with clear-cut edges (passed easily); type
6, ﬂuffy pieces with ragged edges (mushy stool); and type 7,
watery, no solid pieces, and entirely liquid. Patients were
eligible if they fulﬁlled the criteria for the preceding 3
months, with symptom onset at least 6 months before
diagnosis. IBS-D was deﬁned as the presence of loose
(mushy) or watery stools at least 25% of the time and hard
or lumpy stools for less than 25% of bowel movements.
Organic diseases were excluded by total colonoscopy or
double-contrast barium enema in patients aged 50 years or
older and colonoscopy, sigmoidoscopy, or barium enema in
patients aged younger than 50 years. These examinations
were performed within the 5 years before the provisional
registration of subjects and after the onset of IBS symptoms.
According to medical interviews conducted by attending
physicians before provisional registration, patients were
excluded if any of the following were evident: a history of
resection of the stomach, small intestine, or large intestine
(excluding appendicitis or resection of benign polyps);
history or current evidence of inﬂammatory bowel disease;
history or current evidence of ischemic colitis, concurrent
infectious enteritis, concurrent celiac disease, hyperthy-
roidism, hypothyroidism, or other diseases that may affect
gastrointestinal transit or colonic function; history or cur-
rent evidence of abuse of drugs or alcohol within the pre-
vious year; malignant tumors; current evidence of severe
depression or a severe anxiety disorder that potentially
could affect the evaluation of study drug efﬁcacy; concur-
rent serious cardiovascular, respiratory, renal, hepatic,
gastrointestinal (excluding IBS), blood, or neurologic/psy-
chiatric diseases; or history of drug allergies, concurrent
endometriosis, or uterine adenomyosis. In addition, patients
were excluded if they were pregnant or possibly pregnant,
lactating, or wished to become pregnant during the study
period; if they were using drugs or undergoing examina-
tions that could affect the evaluation of study drug efﬁcacy;
if they had been enrolled in previous clinical studies of
ramosetron or had taken ramosetron; and if they were
participating or had participated in other clinical studies
within the 12 weeks before study initiation.
Patients satisfying the inclusion and exclusion criteria
were monitored during a 1-week baseline period during
which data on the severity of abdominal pain/discomfort
and stool consistency were collected to ensure that patients
met the criteria. Severity of abdominal pain/discomfort was
assessed daily on a 5-point ordinate (numeric rating) scale
(0, none; 1, mild; 2, moderate; 3, severe; and 4, intolerable).
Stool consistency was classiﬁed using the BSFS.2 Patients
who had not used drugs or undergone examinations that
could affect the evaluation of study drug efﬁcacy within the
10 days before randomization; who recorded all items in
the patient diary for 5 days or more during the baseline
period; who had mean severity scores for abdominal pain/
discomfort of 0.7 or higher during the baseline period; in
whom no type 1 or 2 stool form, as scored by the BSFS, was
recorded during the baseline period; who had bowel
movements for 5 days or more per week, and who were not
judged ineligible for the study according to the clinical
laboratory test results received before the baseline period
were randomized and subsequently received treatment.
All previously used drugs and previous therapies, which
were used up to 4 weeks before the start of the run-in
period, were investigated. The percentage of patients tak-
ing previous medications for IBS-D was 24.0% (138 of 576)
for all patients enrolled in this study. On a dose-group basis,
the percentages were 25.4% for the placebo group and
22.6% for the ramosetron 2.5-mg group. There was no sig-
niﬁcant difference between the placebo group and the
ramosetron group (Supplementary Table 1).
Supplementary Study Design
Medications other than placebo or ramosetron for IBS-D
were prohibited during the trial period. However, the
following exceptions were made, namely, restricted
concomitant drugs and therapies and rescue drugs, to allow
limited use in accordance with the protocol.
Restricted concomitant drugs and therapies. The
following drugs and therapies were prohibited during the
period from 3 days before the start of the run-in period to
the ﬁnal observation when these drugs or therapies had not
been used before the start of the run-in period: (1) diet
therapy, (2) Chinese herbal medicines (including galeni-
cals), (3) intestinal regulators (eg, Lactobacillus), (4) g-
oryzanol, (5) anxiolytics and toﬁsopam, and (6)
antidepressants.
However, their concomitant use was permissible when
they had been used or administered 4 or more weeks before
starting the run-in period of the study and there were no
changes in their type, dosage, or administration until the
ﬁnal observation.
Rescue drug. In the event of the failure to defecate for
3 or more consecutive days during the treatment period, the
affected patients were to inform the attending physicians of
this fact. If deemed appropriate by the attending physicians,
the patients stopped taking the study drug. The patients
then used one of the rescue drugs: (1) magnesium oxide, 2 g;
(2) magnesium sulfate, 5–15 g; (3) sodium sulfate, 5–10 g;
(4) sodium picosulfate, 5–7.5 mg; (5) bisacodyl, 10 mg;
(6) sennoside, 12–48 mg; (7) senna extract, 80–240 mg; or
(8) senna leaf/senna pod, 0.5–1.0 g.
However, this did not apply to patients who had stool
classiﬁed as normal to watery before drug suspension or
fell into the same classiﬁcation if study drug administra-
tion was only interrupted. If defecation was not induced
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by a rescue drug, the dose of the same rescue drug was
increased or another rescue drug was used at the
discretion of the attending physicians. When defecation
was not induced by any rescue drug, a glycerol enema was
used. After defecation was induced by a rescue drug, the
use of the rescue drug was discontinued. At the time the
stool form was recorded in the patient’s diary (ie, the stool
form that was the most representative [most troublesome]
stool form on that particular day) became normal to
watery, the subject notiﬁed the attending physicians and
administration of the study drug then was resumed at an
appropriate time based on the judgment of the attending
physicians. Rescue drugs could not be used more than
twice. However, if administration of a rescue drug was
required more than twice, that patient was withdrawn
from the study.
Treatment allocation was blinded as follows. Before
assigning the study drugs, the study drug assignment
manager prepared one original and one copy of the random
assignment schedule. After assigning the study drugs, the
study drug assignment manager sealed each of them sepa-
rately, and retained the original. The copy was kept sealed
and retained by the sponsor, even after the treatment code
was broken. The study drug assignment manager also pre-
pared treatment codes to be opened for individual patients
in the event of an emergency, and sealed them after the
assignment. The sealed treatment codes for emergencies
were retained by the person responsible for the treatment
code for emergency. The original of the random assignment
schedule was opened when the statistical analysis plan had
been ﬁnalized and all data had been locked after the
completion of the observations and evaluations for all sub-
jects as speciﬁed in the protocol. At that time, the study drug
assignment manager returned the original assignment
schedule to the sponsor, and the sponsor prepared the re-
cord of its transaction.
Supplementary Data Collection
In the diary, patients recorded BSFS types and stool
frequencies and scored the severity of their abdominal
pain/discomfort on the 5-point ordinate scale. Urgency and
feelings of incomplete evacuation were assessed on a binary
scale (0, absent; 1, present). Every 7 days during the
treatment period, patients also assessed the degree to which
they experienced relief from overall IBS symptoms,
abdominal pain/discomfort, and improvement in abnormal
bowel habits compared with the baseline period. Relief from
overall IBS symptoms and abdominal pain/discomfort were
graded according to a 5-point ordinate scale (0, completely
relieved; 1, considerably relieved; 2, somewhat relieved; 3,
unchanged; and 4, worsened). Improvement in abnormal
bowel habits was scored using a 5-point ordinate scale (0,
nearly normalized; 1, considerably relieved; 2, somewhat
relieved; 3, unchanged; and 4, worsened).
Supplementary Efﬁcacy and Safety End Points
Co-primary end points in this study were the monthly
responder rates for global assessment of relief from overall
IBS symptoms and the monthly responder rate for
improvement in stool consistency at the last evaluation
point. The US FDA proposed a study design for clinical trials
focused on IBS,3 suggesting use of abdominal pain and stool
consistency as co-primary end points for IBS-D. Importantly,
the FDA guidance permits trials of drugs that target only
one of these end points if the mechanism of action of the
drug applies to only one of these symptoms.3 Because our
recent study clearly showed the efﬁcacy of ramosetron in
men with IBS-D, with use of stool consistency as a primary
end point,4 it is reasonable to set the same end point
in women. Patients with weekly mean BSFS scores between
3 and 5 during a week of treatment and a decrease of 1 or
more points in the mean BSFS scores from the baseline
period were regarded as weekly responders. Patients who
were weekly responders for at least 2 of the 4 weeks were
regarded as monthly responders. If more than 2 daily scores
were missing during any week of the study period, the mean
score in that week was deﬁned as missing. Patients with
missing mean BSFS scores were regarded as weekly non-
responders. The last 4 weeks of the treatment phase
constituted the assessment period for the primary end
points.
Supplementary Statistical Analysis
Statistical analysis was performed using SAS Drug
Development (version 3.4) and PC-SAS (version 9.1.3) (SAS
Institute, Inc, Cary, NC). Efﬁcacy analyses included the full
analysis set, which was as complete as possible and as close
as possible to the intention-to-treat ideal of including all
randomized subjects.5 This analysis was in line with the
International Conference on Harmonisation E9, generated
by the regulatory authorities and pharmaceutical industries
of the European Union, United States, and Japan based on
each party’s agreement.5 To determine the robustness of the
results, primary analyses were performed in the per-
protocol set.
From a clinical viewpoint, it is of interest to know if
patients who responded during the ﬁrst weeks remained
responders throughout the entire study period or if there
was a large variation regarding who the responders were
from week to week. Therefore, the continuity of response
was analyzed in patients who were responders in the ﬁrst
week.
Supplementary Results
Supplementary Overall Study Population
Written informed consent was provided by 807 patients.
Of these, 230 patients dropped out and 577 patients were
allocated randomly, and the participation of one patient
from among these was discontinued before the start of
administration. Of the remaining 576 patients, 284 patients
were administered placebo and 292 patients were admin-
istered 2.5 mg ramosetron. The study was completed by 264
patients in the placebo group and 266 patients in the
ramosetron group (Supplementary Figure 1).
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Supplementary Efﬁcacy End Points
Weekly responder rates are shown in Supplementary
Figure 2A and B.
We analyzed the data with the same denominator as used
in themain text and used the samedeﬁnition of a responder as
speciﬁed in the FDA guidance.3 The results showed that the
responder rate for abdominal pain/discomfort in the ramo-
setron group (133 of 292; 45.5%) was signiﬁcantly higher
than that in the placebo group (97 of 284; 34.2%; P ¼ .007).
The responder rate for stool consistency in the ramosetron
group (167 of 292; 57.2%) was signiﬁcantly higher than that
in the placebo group (107 of 284; 37.7%; P < .001). The
composite (abdominal pain/discomfort and stool consis-
tency) responder rate in the ramosetron group (107 of 292;
36.6%)was signiﬁcantly higher than that in the placebo group
(61 of 284; 21.5%; P < .001).
Continuity of response in patients who were responders
in the ﬁrst week is presented in Supplementary Tables 2
and 3. From these data, although it can be seen that a
considerable number of initial responders continued to be
responders at week 12, there was also a large variation in
the continuity of response.
Supplementary Safety
Supplementary Table 4 provides details on gastrointes-
tinal adverse events.
Supplementary Discussion
In the previous phase II and phase III studies, both men
and women were included but efﬁcacy was proven either
only in men or in men and women combined.6,7 The efﬁcacy
of ramosetron had not been conﬁrmed in women with IBS-
D. On the other hand, based on the evidence, alosetron had
been approved only for female patients with diarrhea-
predominant IBS.8 Because it had been suggested that a
gender effect could be a factor in the use of 5-HT3 antago-
nists for IBS-D, ramosetron was approved only for men.
However, there was no logical biological explanation why a
drug from the same class, 5-HT3 antagonists, would be
effective solely in women with IBS-D in Western countries
and only in men with IBS-D in Asia.
The optimal dose of ramosetron for male patients with
IBS-D is 5 mg/day.4,6,7,9 Although a sex-speciﬁc optimal dose
of ramosetron is just as effective in women as it is in men,
several factors underlie the sex-related difference in the
optimal dose of ramosetron. One of the factors in addition to
those described in the main text is serotonin transporter
gene polymorphism. Although serotonin transporter gene
polymorphisms are not likely to produce direct, sex-related
differences in the effect of 5-HT3–receptor antagonists,
5-HT3 antagonists more effectively delay colonic transit
time in subjects with the l-allele than in those with the
s-allele.10 Women in populations that are more l-allele rich
(eg, in the United States11) may be more sensitive to
5-HT3–receptor antagonists than women in s-allele–rich
populations (eg, in Japan11).
In this study, the effect of ramosetron in relation to
stool consistency showed a good RR of 1.68 (95% CI,
1.31–2.15) and an excellent NNT of 7 (95% CI, 5–12). The
RR for constipation with ramosetron was a moderate 2.39
(95% CI, 1.28–4.47). These parameters were better in our
previous randomized controlled trial of male patients with
IBS-D (stool consistency: RR, 2.57; 95% CI, 1.79–3.70; NNT,
3.25; 95% CI, 2.44–4.89; constipation: RR, 5.07; 95% CI,
0.60–42.86)4 than in this study. In a meta-analysis of the
efﬁcacy of alosetron and cilansetron in predominantly fe-
male patients with IBS without constipation or IBS-D, an
RR of 1.60 (95% CI, 1.49–1.72) and a NNT of 4.2 were
reported for improvement of global IBS symptoms.12
Because our present study showed an RR of 1.58 (95%
CI, 1.29–1.94) and a NNT of 6 (95% CI, 4–10) for
improvement of global IBS symptoms, the efﬁcacy of alo-
setron and cilansetron vs ramosetron may be comparable
in women with IBS-D.
In Supplementary Figure 2A and B, weekly responder
rates for IBS symptoms and stool consistency at the last
evaluation point showed a higher value for response than
at any other time point. As in previous studies,4,6,7 the last
evaluation point means the last evaluation week for each
patient regardless of whether the study was completed or
not. Therefore, the last evaluation point shows the efﬁcacy
depend on response for the last week. According to this
protocol, a subject who is not a weekly responder,
including the case in which no assessment could be made
owing to a lack of data, is considered to be a weekly
nonresponder. Any other evaluation point included the
data for patients discontinued at that point as non-
responders. Therefore, the last evaluation point tended to
be associated with a higher value for the response rate than
any other evaluation point.
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Supplementary Figure 1. Flow chart of patient progress throughout the study. Reasons for dropping out of the study are
shown.
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Supplementary Figure 2.Weekly responder rates for primary end points. (A) Weekly responder rates for relief from overall IBS
symptoms. (B) Weekly responder rates for improvement in stool consistency. Height: responder rate (%). Error bar: 95% CI.
P values were calculated using a c2 test, as follows: **P < .01 and ***P < .001.
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Supplementary Table 1.Previous Medications
Generic names of previous medications for IBS Placebo n ¼ 284 Ramosetron n ¼ 292 Total n ¼ 576
Total number (%) 72 (25.4) 66 (22.6) 138 (24.0)
NOTE. There was no signiﬁcant difference in the percentage of patients taking previous medications between the placebo
group and the ramosetron group.
Supplementary Table 2.Durability of Response for Global Assessment of Relief From Overall IBS Symptoms
Evaluation point Treatment Nonresponder Responder Total
Week 1 Placebo 0 (0.0%) 40 (100.0%) 40
Ramosetron 0 (0.0%) 52 (100.0%) 52
Week 2 Placebo 18 (45.0%) 22 (55.0%) 40
Ramosetron 20 (38.5%) 32 (61.5%) 52
Week 3 Placebo 24 (60.0%) 16 (40.0%) 40
Ramosetron 20 (38.5%) 32 (61.5%) 52
Week 4 Placebo 15 (37.5%) 25 (62.5%) 40
Ramosetron 22 (42.3%) 30 (57.7%) 52
Week 5 Placebo 21 (52.5%) 19 (47.5%) 40
Ramosetron 16 (30.8%) 36 (69.2%) 52
Week 6 Placebo 18 (45.0%) 22 (55.0%) 40
Ramosetron 18 (34.6%) 34 (65.4%) 52
Week 7 Placebo 23 (57.5%) 17 (42.5%) 40
Ramosetron 21 (40.4%) 31 (59.6%) 52
Week 8 Placebo 17 (42.5%) 23 (57.5%) 40
Ramosetron 20 (38.5%) 32 (61.5%) 52
Week 9 Placebo 19 (47.5%) 21 (52.5%) 40
Ramosetron 11 (21.2%) 41 (78.8%) 52
Week 10 Placebo 17 (42.5%) 23 (57.5%) 40
Ramosetron 14 (26.9%) 38 (73.1%) 52
Week 11 Placebo 20 (50.0%) 20 (50.0%) 40
Ramosetron 17 (32.7%) 35 (67.3%) 52
Week 12 Placebo 20 (50.0%) 20 (50.0%) 40
Ramosetron 13 (25.0%) 39 (75.0%) 52
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Supplementary Table 3.Durability of Response for Improvement in Stool Consistency
Evaluation point Treatment Nonresponder Responder Total
Week 1 Placebo 0 (0.0%) 28 (100.0%) 28
Ramosetron 0 (0.0%) 81 (100.0%) 81
Week 2 Placebo 16 (57.1%) 12 (42.9%) 28
Ramosetron 40 (49.4%) 41 (50.6%) 81
Week 3 Placebo 16 (57.1%) 12 (42.9%) 28
Ramosetron 46 (56.8%) 35 (43.2%) 81
Week 4 Placebo 16 (57.1%) 12 (42.9%) 28
Ramosetron 45 (55.6%) 36 (44.4%) 81
Week 5 Placebo 14 (50.0%) 14 (50.0%) 28
Ramosetron 48 (59.3%) 33 (40.7%) 81
Week 6 Placebo 17 (60.7%) 11 (39.3%) 28
Ramosetron 40 (49.4%) 41 (50.6%) 81
Week 7 Placebo 15 (53.6%) 13 (46.4%) 28
Ramosetron 46 (56.8%) 35 (43.2%) 81
Week 8 Placebo 20 (71.4%) 8 (28.6%) 28
Ramosetron 41 (50.6%) 40 (49.4%) 81
Week 9 Placebo 14 (50.0%) 14 (50.0%) 28
Ramosetron 44 (54.3%) 37 (45.7%) 81
Week 10 Placebo 14 (50.0%) 14 (50.0%) 28
Ramosetron 44 (54.3%) 37 (45.7%) 81
Week 11 Placebo 16 (57.1%) 12 (42.9%) 28
Ramosetron 45 (55.6%) 36 (44.4%) 81
Week 12 Placebo 19 (67.9%) 9 (32.1%) 28
Ramosetron 49 (60.5%) 32 (39.5%) 81
Supplementary Table 4.Gastrointestinal Adverse Events
Symptoms Placebo (N ¼ 284) Ramosetron (N ¼ 292)
Gastrointestinal disorder 46 (16.2%) 92 (31.5%)
Abdominal discomfort 3 (1.1%) 2 (0.7%)
Abdominal distension 1 (0.4%) 3 (1.0%)
Abdominal pain, lower 0 (0.0%) 1 (0.3%)
Abdominal pain, upper 5 (1.8%) 5 (1.7%)
Constipation 13 (4.6%) 32 (11.0%)
Diarrhea 1 (0.4%) 0 (0.0%)
Dyspepsia 0 (0.0%) 1 (0.3%)
Enterocolitis 0 (0.0%) 1 (0.3%)
Feces hard 16 (5.6%) 66 (22.6%)
Flatulence 1 (0.4%) 0 (0.0%)
Gastritis 1 (0.4%) 0 (0.0%)
Gastroesophageal reﬂux disease 1 (0.4%) 0 (0.0%)
Irritable bowel syndrome 1 (0.4%) 0 (0.0%)
Melena 0 (0.0%) 1 (0.3%)
Nausea 2 (0.7%) 2 (0.7%)
Periproctitis 2 (0.7%) 1 (0.3%)
Proctalgia 1 (0.4%) 0 (0.0%)
Stomatitis 1 (0.4%) 1 (0.3%)
Vomiting 0 (0.0%) 2 (0.7%)
Anal hemorrhage 1 (0.4%) 0 (0.0%)
Anal pruritus 1 (0.4%) 0 (0.0%)
Anorectal discomfort 1 (0.4%) 0 (0.0%)
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